Recital 25, Directive (EU) 2001/83

In forcecited 1×

The usual rules governing the authorization to market medicinal products should be applied to homeopathic medicinal products placed on the market with therapeutic indications or in a form which may present risks which must be balanced against the desired therapeutic effect. In particular, those Member States which have a homeopathic tradition should be able to apply particular rules for the evaluation of the results of tests and trials intended to establish the safety and efficacy of these medicinal products provided that they notify them to the Commission.

  • Judgment of the Court (Eighth Chamber) of 23 April 2020. Deutsche Homöopathie-Union (DHU) Arzneimittel GmbH & Co. KG v Bundesrepublik DeutscDecision

    It follows from Article 16(1) of Directive 2001/83, read in the light of recital 25 thereof, that homeopathic medicinal products placed on the market with therapeutic indications or in a form which may present risks are subject to the …

    23 Apr 2020 · 62019CJ0101